Remove 2017 Remove Chemotherapy Remove Pharmaceutical Companies
article thumbnail

2nd Hit ID Summit

pharmaphorum

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

Pharmaceutical companies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. In 2007, he became in charge for business development and in 2017, also became responsible of the portfolio strategy.

article thumbnail

Amgen's Five Prime takeover delivers gastric cancer win

pharmaphorum

billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal.

article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. As a result, many large pharmaceutical firms have dropped out of the market in favour of pursuing more profitable areas of drug development, such as oncology.